CONTENTS OF VOLUME 1, 2, 3, 4 AND 5

THROMBOSIS RESEARCH

AN INTERNATIONAL JOURNAL ON VASCULAR OBSTRUCTION, HEMORRHAGE AND HEMOSTASIS

EDITORS-IN-CHIEF: ALFRED L. COPLEY, NEW YORK, U.S.A., AND BIRGER BLOMBÄCK, STOCKHOLM, SWEDEN

Dear Reader:

I am pleased to bring to your notice the aims and scope, table of contents and Author Index of recent issues of this journal together with an invitation to consider submitting suitable manuscripts for the journal. I hope very much that you will be good enough to examine this material and, where necessary in consultation with your colleagues, that you will decide to recommend the purchase of a subscription to the journal by your main or departmental library.

If the library in your organization is either a subscriber already or becomes a subscriber then you or any colleague who may be interested can obtain a personal subscription at the reduced rate of $25.00.

On the back pages you will also find information about some important reference works and textbooks published by Pergamon Press, some of which we hope you will find of interest.

Thank you in advance for your kind consideration of these matters.

Yours sincerely,

Robert Maxwell
Publisher

Published By
Pergamon Press • NEW YORK • OXFORD

THROMBOSIS RESEARCH

AN INTERNATIONAL JOURNAL ON VASCULAR OBSTRUCTION, HEMORRHAGE AND HEMOSTASIS

EDITORS-IN-CHIEF: ALFRED L. COPLEY, NEW YORK, U.S.A., AND BIRGER BLOMBÄCK, STOCKHOLM, SWEDEN

AIMS & SCOPE:

THROMBOSIS RESEARCH serves as a world forum for the rapid dissemination of original research on thrombus formation, thrombo-embolization, hemorrhage due to alterations of the blood vessel wall and/or defects in hemostasis, and other related hemorheological disturbances which impair circulation. The Editors welcome scientific contributions which give new directions to research on thrombosis and allied pathological conditions. The Journal's policy encourages the publication of manuscripts of research concerning these conditions, including clinical investigations which will lead to new approaches in diagnosis, therapy, prognosis, and prevention of thrombosis and other hemorheological diseases or disorders. Reports and brief communications should pertain to: (1) processes such as the activation of thrombin, the formation, polymerization, gelation and lysis of fibrin, the aggregation and desaggregation of blood cellular elements, as well as of plasma proteins, and (2) rheological and other physical properties of blood, the different blood vessels and their walls, thrombi, blood cellular clumps, fibrin gels, among others.

THROMBOSIS RESEARCH provides for the rapid publication of contributions. A special editorial policy and handling procedure for manuscripts has, therefore, been established. Each Editor has the responsibility to decide the acceptance of a manuscript submitted to him. Authors are requested to send their manuscripts to an Editor of their choice, preferably one in their own country or regional proximity for rapid handling. The Editor is required to have the manuscript appraised by two referees, and may act as one of them. The Editor's decision is based on these appraisals. Upon acceptance of the contribution, the Editor sends the manuscript together with the appraisals to the Editor-in-Chief. The paper will then be published and the name of the Editor will appear as follows:
(Received DATE. Accepted by Editor NAME).

The Journal will publish papers in English, French, German, and Russian. The author is requested to write in whichever of these languages he knows best. All papers, except brief communications, must have an abstract in English.

A complete list of Editors and addresses is included in this issue.

Published monthly. Annual subscription rate $85.00; 2 year subscription (1976/77) $161.50. Special reduced rates for individuals: In the interests of maximizing the dissemination of the research results published in this important international journal, we have established a two-tier price structure whereby individuals whose institution takes out a library subscription, may purchase a second or additional subscription for their personal use at a much reduced rate of U.S. $25.00 per annum. Subscriptions are entered on a calendar year basis only. Airmail subscriptions extra.

Publishing Offices:

PERGAMON PRESS, INC.
Maxwell House, Fairview Park
Elmsford, New York 10523 U.S.A.

PERGAMON PRESS LTD.
Headington Hill Hall
Oxford OX3 0BW, England

Advertising Offices:

PERGAMON PRESS, INC.
395 Saw Mill River Road
Elmsford, New York 10523 U.S.A.

PERGAMON PRESS LTD.
Headington Hill Hall
Oxford OX3 0BW, England

Microform Subscriptions and Back Issues: Current subscriptions on microfiche, and back files on microfilm as well as back issues in the paper editions of all previously published volumes are available from: Pergamon Press and/or its division, Microforms International Marketing Company, Fairview Park, Elmsford, New York 10523 U.S.A. or Headington Hill Hall, Oxford, England.

Statement: No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means: electronic, electrostatic, magnetic tape, mechanical, photocopy, recording or otherwise, without permission in writing from the publishers.

Copyright © 1976 Pergamon Press, Inc.

Cover by L. Alcopley

T H R O M B O S I S R E S E A R C H

CUMULATIVE AUTHOR INDEX AND SUBJECT INDEX

VOLUMES: 1, 1972; 2, 3, 1973; 4, 5, 1974.

Compiled by

Barbara Kowalska-Loth, Ph.D.

Instytut Badan Jadrowych, Warsawa 9, Poland

and

Una Dora Copley, B.A., Editorial Assistant

Executive Editorial Office, Thrombosis Research Laboratory of Biorheology, Polytechnic Institute of New York, Brooklyn, New York 11201, U.S.A.

PERGAMON PRESS, NEW YORK, U.S.A. AND OXFORD, ENGLAND

AUTHOR INDEX

Abildgaard,C.F. 5,375
Abildgaard,U. 4,147; 5,185
Adams,A.L. 1,507
Adamson,C. 3,87;4,485
Agrawal,B.B.L. 1,209,443;2,293
Akinsete,F.J. 3,489
Alexander,B. 1,581;3,327;4,567
Alexandre,P. 4,319
Alkjaersig,N. 3,525
Allington,M.J. 5,413
Almer,L.O. 1,59
Almqvist,I.A.M. 1,487
Alter,A. 3,59
Anan,K. 4,639
Andary,T.J. 4,869
Andersson,L.O. 5,439
Anderton,J.L. 3,219
Ardaillou,N. 1,283;5,327
Arfors,K.E. 1,487;3,75,565;4,77, 345,447
Arnesen,H. 2,173;3,643;4,861;5, 93,301
Astedt,B. 3,413
Astrup,T. 4,609
Auran,T.B. 5,173

Bagdy,D. 2,229
Bagge,L. 2,365
Ballantyne,D.L.Jr. 4,177
Banerjee,S. 2,487;3,451;5,47,581
Bang,N.U. 5,719
Barabás,E. 2,229
Barlow,G.H. 1,201;2,17,115,123;5,695
Basu,A.K. 1,281
Baskova,J.P. 3,91
Baumgartner,H.R. 3,715
Beck,E.A. 3,553
Belitser,V.A. 2,567;3,251,265
Benner,K.U. 2,331
Bergentz,S.E. 1,427;4,271;5,1
Bergqvist D. 3,75;4,77,345,447,479
Bergström,R. 4,719
Bernard,C. 1,i
Bibbens,J.D. 5,633
Bierme,R. 3,605
Björntorp,P. 1,389,407
Blatt,S.J. 4,387,399
Blätter,W. 4,787
Bleyl,H. 2,361
Blombäck,B. 1,iii,113,161,267,371, 435,539;2,1,3,183,297,423;3,231; 4,55,615;5,223,583,621,685
Blombäck,M. 1,267;4,55,719;5,621
Bloom,A.L. 1,323;3,389;5,585
Bonaccorsi,A. 4,189
Boneu,A. 3,605
Boneu,B. 3,605
Borg,H. 5,439
Bottecchia,D. 2,71;3,425;5,431
Bouma,B.N. 4,155;5,33
Bourgain,R.H. 4,599
Bowie,E.J.W. 2,251;3,501;4,247, 383;5,479
Boyd,T.H.,III.3,209
Brecher,A.S. 5,157
Briginshaw,G.F. 4,463
Brinkhous,K.M. 1,197
Brozović,M. 2,557
Brunner,R. 2,331
Buczko,W. 2,219
Buluk,K. 5,571
Burkholder,D.E. 5,157
Burkholder,J.S. 5,157
Busch,C. 2,365;3,1
Buyniski,J.P. 5,633

Capet-Antonini,F.C. 2,479
Caprini,J.A. 4,199;5,379
Cash,J.D. 2,9,23;3,51,137,219; 4,25
Caspar,C. 3,281
Castaldi,P.A. 4,653;5,787
Cavanagh,R.L. 5,633
Cederholm-Williams,S.A. 5,413
Chan,P.S. 5,529
Chang,M.L. 5,719
Chesterman,C.N. 5,413
Chisolm,G.M. 4,699
Claeys,H. 3,515
Clancy,R. 3,375
Clarkson,A.R. 2,9
Coburn,R.J. 4,177
Cohen,I. 5,83,261
Cole,E.R. 4,551
Collen,D. 2,239;4,491;5,777

Cooper,H.A. 2,251
Copley,A.L. 1,iii,1,279,337,435, 439;2,1,183,487;3,231,451;4,1,193, 385,615;5,47,581,583,781
Cortellaro,M. 3,13
Creatchman,T. 2,451
Crompton,G.K. 3,137
Cronberg,S. 3,405
Csalay,L. 3,545
Cybulska,J. 4,137
Czervionke,R.L. 4,879

Dancewicz,A.M. 2,41
da Costa,J. 3,51;4,25
Danishefsky,J. 1,173;4,237
Davies,J.A. 5,69
Davies,T. 5,69,667
Davis,S. 2,451
de Cock,F. 5,777
de Gaetano,G. 1,631;2,71,97;3,425; 4,189;5,431
de Graaf,S. 4,155
de Vries,A. 5,83,261
Degtyaryova,I.I. 3,265
Deutsch,E. 3,103
Devi,A. 2,487;3,451;5,47,581
Devine,E.M. 5,695
Diffang,C. 5,263
Doctor, V.M. 1,311,317
Dombrose,F.A. 1,293;3,737
Donahoe,J.F. 2,115
Donati,M.B. 1,631;2,97;4,189
Douglas,A.S. 3,489
Dudek-Wojciechowska,G. 2,271,283
Dyr,J.E. 5,213

Eckenhoff,J.B. 5,379
Eckner,F.A.O. 4,387,399
Edgar,W. 2,85
Egington,T.S. 1,605
Egberg,N. 1,95,637;2,423;3,191;4,35
Eika,C. 2,155,349
Ekelund,H. 5,601
Ekelund,L. 3,413
Ekert,H. 5,111
Ellenbogen,L. 5,529
Ellingsen,R. 5,539
Engel,A.M. 1,581
Esmon,C.T. 2,509
Estrin,J. 3,59
Evans,E.P. 1,323

Fabiani,P. 3,339
Fagerhol,M.K. 4,147
Fasco,M.J. 4,809
Fass,D.N. 3,501;4,383;5,479
Faust,G. 2,383
Feddersen,C. 5,125
Fenton,J.W.,II 4,809
Finkbeiner,W. 4,55
Finkelstein,A.E. 4,567
Finlayson,J.S. 2,467;4,895
Finley,R. 2,17,115
Firkin,B.G. 3,375;5,557,565
Flessa,H.C. 1,253
Fletcher,A.P. 3,233,525
Flier,O.Th.N. 5,197
Forestieri,H. 4,219
Forbes,C.D. 1,493;3,363;4,375
Francey,T. 3,35
Franco,R. 4,189
Fresh,J.W. 3,67
Friedlander,S. 2,451
Fujimoto,K. 4,731
Fumarola,D. 4,819
Furie,B. 4,219
Furlan,M. 3,553
Fuster,V. 4,247

Gabbay,J. 5,83,261
Gader,A.M.A. 2,9;3,51,137,219; 4,25
Gaffney,P.J. 2,105,201;5,235
Galanova,T.F. 3,265
Garattini,S. 4,189
Gårdlund,B. 1,371,539;2,423,539
Gasic,S. 3,103
Gastpar,H. 5,277
Gautheron,P. 1,353
Gavrilis,P. 4,335
Gerrits,W.B.J. 5,197
Giddings,J.C. 3,389;5,585
Girgis,N.J. 3,67
Gjönnaess, H. 4,769
Gladecki,K. 4,137
Glaser,T. 5,83,261
Gleason,E.M. 5,99
Glenn,C.H. 5,735
Glueck,H.J. 1,253;3,477
Godal,H.C. 2,155,173;4,707;5,773
Goh,A. 5,565
Goldstein,R. 4,165,335
Göransson,L. 3,161
Gorman,P.A. 4,653;5,787
Gormsen,J. 5,125
Govaerts,A. 5,141
Graeff,H. 3,183,465
Gráf,L. 2,229
Gravem,K. 4,707;5,21
Grimard,M. 2,479
Groben,H.D. 1,443

Gröndahl,N.J. 1,371,539;4,131
Gross,R. 3,307
Guillin,M.C. 3,117
Guiraud,R. 3,605
Gurd,L. 2,557
Gurewich,V. 1,569;2,539;4,891;
5,343,647
Gustavsson,A. 1,407
Gutova,M. 1,127

Haerem,J.W. 5,243
Hafter,R. 3,465
Hagen,I. 3,307
Hahn,L. 4,417;5,437
Hansen,M.S. 5,719
Hardisty,R.M. 4,617
Harper,A.D. 4,177
Hassouna,H.I. 4,875;5,421
Haugen,G. 4,769
Hauptmann,J. 2,383
Hawthorne,G.A. 4,177
Hedner,U. 1,59,427;3,631
Heene,D.L. 2,137;3,657,745;4,803
Helliger,H. 5,111
Henriksson, P. 5,453
Herbert,R.J. 3,489
Hewett-Emmett,D. 5,421
Hijikata,A. 4,731
Hindersin,P. 5,613
Hint,H.C. 1,487
Hladovec,J. 3,665
Hoak,J.C. 2,261;4,879
Hocke,M. 1,541
Hoffmann,J. 2,343
Hogg,D.H. 5,685
Holme,R. 3,347;4,377
Holmgren,A. 4,55
Hoq,M.S. 2,23
Hörmann,H. 4,753
Horowitz,M.S. 1,113
Hovig,T. 3,347;4,377
Howard,M.A. 4,617
Howarth,D.J. 2,557
Howe,W.F. 5,157
Hudry-Clergeon,G. 4,89
Hufnagel,L. 5,461
Hume,M. 4,757

Ijiri,H. 4,639
Imanishi,H. 5,633
Ingerman,C.M. 5,291
Irwin, F.J. 5,469
Iwanaga,S. 1,619

Jackson,C.M. 2,509;3,705
Jacobsen,C.D. 2,261
Jakobsen,E. 3,145;4,499,509;5,21
Janssen,C.L. 2,525;5,315
Jaques,L.B. 2,377;3,295
Jelenska,M.M. 2,41
Johnsson,H. 1,95,135;4,229
Josso,F. 1,183
Jones,G.R. 1,323
Juraschek,H. 4,741

Kahn,M.J.P. 5,141
Kakkar,V.V. 4,303;5,235
Kamiński,M. 5,571
Kavanagh,L.W. 3,295
Kaye,M.P. 4,387,399
Kazmier,F.J. 4,247
Kemp,G. 3,553
Kierulf,P. 1,527;2,155,173;
3,145,613;4,183,499,509;
5,21,185,301
Kim,S.W. 3,87;4,485
King,R.G. 1,1;4,193
Kitaguchi,H. 4,731
Kleniewski,J. 4,137
Klings,M. 1,507
Klöcking,H.P. 1,243;2,383
Kloczewiak,M. 2,271,283
Knüll,W. 4,741
Kocsis,J.J. 5,291
Konradi,E. 3,657
Kopeć,M. 2,41,177,271,283;
5,359
Körbs,E. 2,343
Korsan-Bengsten,K. 1,389,407,549
Körting,H.J. 5,613
Korvald,E. 4,147
Kosow,D.P. 4,219
Koutts,J. 5,557
Kovács,J.B. 3,545
Kowalska-Loth,B. 1,371,539;2,
423;4,55
Krause,W.H. 2,361
Krivit,W. 5,173
Kubisz,P. 4,119
Kudrjashov,B.A. 3,589
Kudryk,B. 2,297
Kuo,S.H. 3,295
Kwaan,H.C. 2,31,115,123;4,199

Laake,K. 2,393,409;4,103,285,
707,769;5,539,759,773
LaBruyère,W.T. 4,155
Lagergren,H. 4,687
Larcan,A. 4,319
Larrieu,M.J. 1,183;5,327
Larsson,K.S. 1,127
Lasker,S.E. 1,337
Latallo,Z.S. 2,271,283;5,719
Latchem,S. 2,451

Lavergne,J.M. 1,183
Lazer,L.V. 1,201;2,115
Lederer,D.A. 5,69,667
Lee,R.G. 3,87;4,485
Leonardi,R.G. 3,327
Lerner,R.G. 4,165,335
Levine,S. 3,59
Lewis,J.H. 3,67,419
Lewis,L.J. 2,17;4,879
Liapina,L.A. 3,589
Limber,G.K. 5,735
Lindemans,J. 5,33
Linker,H. 3,307
Lipińska,I. 2,539;4,891;5,647
Lipiński,B. 1,569;2,539;4,891;5,343,647
Lipton,S. 3,59
Ljungqvist,A. 3,161,191
Ljungqvist,U. 4,271;5,1
Lowenhaupt,R.W. 3,477
Lucas,T.R. 4,699
Luft,S. 2,177
Lundblad,R.L. 1,197
Ly,B. 3,643;4,499,509;5,21,93,301
Lyman,D.J. 3,87;5,709

Macdonald,G.J. 5,657
Macfarlane,D.E. 5,401
Mackenzie,R.D. 5,99
Malinowska,L. 2,219
Malisardi,P. 3,13
Mammen,E.F. 5,469
Mandel,E.E. 3,437;4,497
Manyakov,V.Ph. 2,567;3,265
Manko,N.I. 3,265
Mannucci,P.M. 4,539
Mann,B. 2,305
Mann,K.G. 3,501;4,383
Marcel,G.A. 3,281
Markwardt,F. 1,243;2,343,383
Marguerie,G. 3,675
Mars,G. 3,13
Martin,D. 2,17
Martin,M. 4,741
Martin,U. 4,741
Mason,R.G. 5,735,747
Matell,G. 3,173
Matsuda,M. 1,619
Matthias,F.R. 2,137;3,657,745;4,803
Mattler,L.E. 5,719
McCoy,L.E. 1,33,209,221,293,443,461,533;2,293;3,357;4,713,829,885;5,421
McCullough,W. 1,311
McDonagh,J. 1,147
McDonagh,R.P.Jr. 1,147
McElroy,F. 3,35
McIntosh,M. 1,559;2,461
McKenzie,F.N. 3,75,565
McNicol,G.P. 5,69,667
Menaché,D. 3,117
Mester,L. 4,327
Metcalf,L.C. 5,709
Meyer,D. 1,183
Miller-Andersson,M. 5,439
Miller,M.A. 3,477
Mills,D.C.B. 5,401
Minn,S.K. 3,437;4,497
Mochtar,J.A. 4,155
Mockros,L.F. 5,379
Mok,A. 2,451
Molla,A. 3,515
Molony,B.A. 3,577
Montgomery,D.C. 4,617
More,R.H. 2,451
Morgan,F.J 5,565
Mosesson,M.W. 2,185,467;4,895
Moylan,D.S. 5,633
Muggli,R. 3,715
Mullen,B. 2,451
Müller-Berghaus,G. 1,473,541;2,305
Muntz,R.H. 5,111
Murano,G. 1,161,209
Mürer,E.H. 3,347;4,377
Murray,M. 4,261

Nafstad,I. 5,251
Nakamura,S. 1,619
Nathan,P. 4,177
Nicolas,A. 4,319
Niklasson,P.M. 4,229
Nilsson,G. 3,75
Nilsson,I.M. 1,59;3,631
Nilsson,L.A. 1,549
Nishizawa,E.E. 1,233;3,577
Nivenius-Larsson,K. 3,405
Norén,I. 1,19
Nossel,H.L. 5,495
Nowak,A. 5,343
Nyman,D. 2,323;3,173

Ødegård,O.R. 3,643;5,185
Ogston,D. 3,489
Ohlmeyer,P. 1,337
Okamoto,S. 4,731
Olovson,G. 4,55
Olson,J.D. 3,501;4,383;5,479
Olson,P.S. 3,1;4,271;5,1
Olsson,P. 1,135,267;3,161;4,687;5,621
Österud,B. 5,759
Owen,C.A.Jr. 2,251;4,247;5,479
Owen,W.G. 1,71;3,705

Pankiewicz,A. 2,271,283
Parker,S.M. 3,51,137
Parts,A. 1,581
Pasquetto,N. 4,819
Paturel,L. 4,89
Peake,I.R. 3,389;5,585
Pepper,D.S. 5,185
Peyer,A. 4,787
Philp,R.B. 3,35;4,361
Pilgeram,L.O. 5,519
Pirkle,H. 1,559;2,461;5,511
Plow,E.F. 1,605
Podolsak,B. 3,307
Pollini,C. 3,13
Pomianowska,L. 2,177
Pouit,L. 3,675
Praga,C. 3,13;5,699
Prentice,C.R.M. 1,493;2,85;3,363;4,375

Raisson,C. 3,605
Rammer,L. 2,365
Ramstack,J.M. 5,379
Rapin,M. 3,281
Rearick,D.E. 4,261
Renaud,S. 1,353
Reuter,C. 1,473
Reuter,H. 3,307
Reuterby,J. 1,209;2,297;4,713,829,875,885;5,421
Riddle,J.M. 5,461
Roisman,F. 4,567
Rosa,A.T. 4,609
Rossmann,P. 3,665
Roy,L. 3,525
Rowlands,S. 1,47
Rubin,H. 3,59
Rygh,M. 5,773

Saba,S.R. 5,747
Sabatier,C. 3,281
Sakuragawa,N. 1,33,209,221,293,443
Saldeen,T. 2,365;5,263
Samama,M. 3,339;4,327
Sano,T. 4,625,639
Sawa,T.R. 1,233
Sawecka,J. 5,359
Sawers,R.J. 5,557
Sawyer,P.N. 4,699
Schäfer,G. 4,741
Schneider,M.D. 4,387,399
Schultz,J.R. 1,233
Scully,M.F. 4,303;5,235
Sedensky,J.A. 1,293
Seegers,W.H. 1,33,209,221,293,443,461,533;2,293;3,23,357,737;4,437,713,829,869,875;5,421,703
Semeraro,N. 4,491,819
Senicas,V. 2,451
Shadid,J.N. 3,691
Shanberge,J.N. 4,463
Sharp,A.A. 5,413
Shearn,S.A.M. 5,585
Shepherd,B. 1,311
Sherman,L.A. 4,901
Shimamoto,Takio 4,625,639
Shimamoto,Tatsuo 4,625
Silver,M.J. 5,291
Silverstein,R.M. 3,729;4,675
Sirs,J.A. 5,657
Siskovic,E. 1,173
Six,F. 4,599
Sixma,J.J. 3,347;4,377;5,33
Sjöström,L. 1,389,407
Skansberg,P. 3,405
Skibo,L. 1,47
Smechova,E.A. 3,265
Smith,J.B. 5,291
Smith,S.M. 1,493
Solum,N.O. 2,55
Soria,C. 3,339;4,327
Soria,J. 3,339;4,327
Spanondis,K. 5,495
Spencer,A.A. 5,667
Srinivasan,S. 4,699
Stemberger,A. 4,753
Stenberg,J. 1,389
Stocker,K. 2,17
Stoltz,J.F. 4,319
Stoner,G.E. 3,209;4,699
Stormorken,H. 5,375
Stott,L. 5,557
Strachan,C.J.L. 4,303;5,235
Straub,P.W. 4,787
Streiff,F. 4,319
Ströder,J. 3,307
Strukova,S.N. 3,91
Sullivan,L. 1,389
Sumiyoshi,A. 2,451
Suranova,J. 4,119
Suscillon,M. 3,675;4,89
Suydam,D.E. 1,233;3,577
Suwanwela,N. 2,123
Svanberg,L. 3,413;5,453
Svendsen,L. 1,267;5,621
Svensjö,E. 1,427
Swedenborg,J. 4,687
Szczepański,M. 4,587
Szumiel,I. 5,359

Tamenasse,J. 2,479
Tangen,O. 1,487;3,565;4,479
Taylor,C.H. 5,633

Teger-Nilsson,A.C. 4,131;5,223,601
Teisseyre,E. 2,283
Theodor,I. 1,559;2,461;5,511
Thompson,R.J. 5,99
Thomson,C. 3,363,4,375
Tibblin,G. 1,549
Tobin,H.G. 4,387,399
Triantaphyllopoulos,D.C. 3,241
Tsernoglou,D. 1,533
Tsinkalovska,S.N. 3,251
Tzeng,F. 4,237

Ulianov,A.M. 3,589

Vainer,H. 1,283;4,523
Van der Meer,J. 5,197,315
Van Leeuven,W.H. 2,525
Van Mourik,J.A. 4,155
Varetska,T.V. 2,567;3,251,265
Venneröd,A.M. 2,393,409;4,103,285,769
Verduin,R. 4,199
Vermylen,J. 1,631;2,71,97,239;
3,425;4,819;5,431
Vernon,S. 1,559;2,461
Verry,M. 4,523
Verstraete,M. 3,515;4,491
Vodrážka,Z. 5,213
Von dem Bussche,G. 5,519
Von Hugo,R. 3,183,465
Von Kaulla,K.N. 4,367
Vroman,L. 1,437,507

Wagner,R.H. 1,71
Wallenbeck,I.A.M. 4,479
Walz,D.A. 1,533;2,293;3,357;4,713,829,
875,885;5,421
Webster,W.P. 1,197
Wegrzynowicz,Z. 2,41;4,803;5,359
Weigensberg,B.J. 2,451
Werner,B. 3,173
Wetmore,R. 5,343
White,F. 3,327
Wiener,J. 4,165
Wijngaards,G. 2,525;5,315
Wik,K.O. 1,487
Wilhelmsen,L. 1,549
Wilhelmsson,S. 3,173
Wilson,J.H. 3,419
Wilman,B. 1,89,161
Wiśniewski,K. 2,219
Wolf,E. 4,757
Wollin,A. 2,377
Woods,K.R. 1,113
Wynalda,D.J. 1,233;3,577

Yamazaki,H. 4,625,639
Yassin,M.W. 3,67
Yudelman,I. 5,495

Zajdel,M. 5,359
Zavoral,J.H. 5,173
Zolton,R.P. 3,23;4,437;5,461
Zuch,A. 5,571
Zuckerman,L. 4,199;5,379
Zwiener, 5,613

SUBJECT INDEX

Ac-globulin 5,703
Acetyl salicylic acid 1,135
Adenosine diphosphate (ADP)
  breakdown in normal & uremic plasma 1,323
  effect on Reptilase clot retraction 4,189
Adenylate cyclase & prostaglandin D_2 5,401
Adhesiveness
  platelet-collagen test 5,99
Adrenaline
  effect on factor VIII level 1,493;2,9;3,137;4,25
  effect on fibrinolytic, factor VIII & pulse rate reponses during salbutamol adminstration 3,137
  effect on plasminogen activator 2,9;3,51;4,25
Adrenergic agonists
  effect on plasminogen activator and factor VIII 2,9
Affinity chromatography
  fibrin agarose
    adsorption of fibrinogen derivatives 2,137
  fibrin monomer produced by Reptilase
    chromatography of fibrinogen & fibrinogen degradation products 3,745
  fibrin monomer produced by thrombin
    chromatography of fibrinogen degradation products 3,657,745
  fibrinogen-agarose
    adsorption of fibrinogen derivatives 2,137
    chromatography of fibrin monomer, fibrinogen degradation products 3,657
    reduction of dissulfide bonds 4,803
  fibrinogen-Sepharose (thrombin modified)
    adsorption of fragment D 2,297
Affinity chromatography
  heparin-agarose
    interaction with plasma 4,297
  heparin-Sepharose
    purification of antithrombin III 5,439
  L-lysine-Sepharose
    plasminogen purification 4,679
    purification of fibrinogen free from plasminogen 1,619
Aggregation of
  fragments D & E, soluble fibrin complex formation 5,719
  platelets, defective 1,323
Ancrod and thrombin clotting units 5,695
Anticoagulant agent
  glucuronolactone 1,311,317
  hirudin 2,229
  Liquoid, effect on fibrinogen, platelet aggregation, comparison with heparin 2,155
  1,4-saccharolactone 1,311
  Trasylol, effect on fibrin deposition & elimination 5,263
Antigen, factor VIII in platelets 5,585
Antihemophilic factor 1,71
Antithrombin
  assay 5,621
  inhibition of prethrombin-E, thrombin & thrombin-E 4,869
Antithrombin III
  factor VII inactivation 5,773
  inhibition by Liquoid 2,155
  level in various diseases 3,631
  purified factor VII 5,773
  purification, heparin-Sepharose 5,439
Antithrombotic effect
  synthetic thrombin inhibitors 1,243
Antisera
  factor VIII, related antigen in platelets 5,585
Arginine esterase
  kaolin induced during septic shock 3,281

Arginyl bonds
human prothrombin 5,511
Arterial thrombosis
in vivo studies 5,529
Arteries, ear
laser-induced injuries 5,529
Aspirin
effect on bleeding time 3,13
effect on blood coagulation 5,69
effect on platelet
aggregation,ristocetin-induced 3,501
changes induced by exercise 5,69
-collagen interaction 5,99
membrane 1,631
release reaction, inhibition, prevention by prostaglandins precursors 3,327
Autoprothrombin II-A
fibrinolysis induction,mechanism 3,23
purification,properties 1,443
structure 5,461
Autoprothrombin III
effect on coagulation tests in deficient plasmas 1,221
light & heavy chain isolation, comparison to prothrombin 2,293
purification,characteristic 1,209
Autotransfusion of plasma in von Willebrand's disease 5,479

β lipoprotein 4,193
Benzoyl-DL-arginine-β-naphthylamide
evaluation 5,157
Biorheology,Second International Congress:Announcement 5,577
Bis-tetrahydroisoquinolines
fibrinolytic effect 5,633
BL 191 (Pentoxifylline)
inhibition of cancer cell stickiness 5,277
Bleeding time
Copley-Lalich 4,1
Duke 4,1
Ivy 4,1;5,781
effect of antiaggregating drugs 3,13
in clinical pharmácology 5,699
Blood clotting
effect of aspirin 5,69
effect of carbohydrates 1,407
effect of exercise 1,389
effect of polyethylene glycol 4,809
effect of snake venoms 2,487;3,451
factor VII activation 5,759
Blood clotting
flurbiprofen 5,667
mechanism 1,293
in obese subjects 1,389
relation to blood groups 1,549
Blood
fluidizing activity 3,691
groups
relation to blood clotting and fibrinolysis 1,549
platelet polylysine reactivity 5,709
thrombin activity in benzoyl-DL-arginine-β-naphthylamide 5,157
umbilical cord
fibrinogen to fibrin transformation 5,601
vessel wall structure 4,699
Bothrops atrox venom
light scattering studies 1,337
Brinase, degradation of fibrin clots 5,125
Bromide, cyanogen
cleavage with N-terminal fragment of human plasminogen 1,89
Brussels prothrombin 5,141

Calcium ions,plasma euglobulin lysis 5,613
Cancer cell stickiness
inhibition by methylxanthine derivative pentoxifylline 5,277
Capillary fragility 4,1
Capillary permeability 4,1
Capillorrhage 4,1
Ceruloplasmin
ADP-induced platelet aggregation 4,327
Çhatterjea, J.B.
obituary 1,279,281
Chlorpromazine
platelet-collagen interaction 5,99
Chromatography affinity
purification of antithrombin III 5,439
Chromogenic substrates
synthetic 1,267;5,621
Chymotrypsin
degradation of fibrin clots 5,125
Clinical pharmacology
bleeding time 5,699
Clot contraction-relaxation waves
effect of energy metabolism inhibitors 5,83,261.
Clot retraction
effect of ADP & prostaglandin E_1 4,189

Clot retraction
effect of staphylocoagulase 4,819
endothelial cells 5,747
induced by platelet aggregating agents 2,323
relaxation, effect of prostaglandin E_1 5,431
Clottable plasma proteins during fibrinogenolysis 5,301
Clotting conditions & FDP 5,437
Clotting, factor components 1,33
Clot weight method, modified 5,213
Coagulation
fibrinolytic neoantigens in plasma 5,777
flurbiprofen 5,667
intravascular, induced by thrombin or thromboplastin 5,263
low pH: Fr-antigens in serum 5,93
Coagulopathy
by boomslang bite, therapy 3,173
Collagen
action on factor X & Xa 1,581
on platelet aggregation 3,175
-induced thromboembolism 1,233
modified, interaction with platelets 2,41
effect of chlorpromazine, EDTA, aspirin 5,99
Conference report: Fibrinogen & its derivatives 2,3
Contraction-relaxation waves in platelet rich clots 5,83;5,261
Copley-Lalich bleeding time 4,1
Coronary disease
platelet aggregates & mural microthrombi 5,243
Cross-reacting material in congenital factor VIII deficiencies 1,173
Crotalidae venom
electrophoretic analysis 3,451
Cyanogen bromide
cleavage with N-terminal fragment 1,89
Cyclic AMP
in fibrinolytic system, effect on plasminogen activator 4,539

Defective protein
prothrombin Brussels 5,141
Defibrinated dogs & Reptilase 1,95
Defibrase and sodium salicylate on pregnant mice 1,127
Deficiency of plasma clotting factors
factor VII, IX & X deficiency
effect of purified factor X on coagulation tests 1,221
Deficiency of plasma clotting factors
Hageman factor deficiency
activation of plasminogen proactivator-activator system by dextran sulfate 4,609
Determination of activated factor V 5,315
Dextran
alteration in fibrin structure 1,487
effect on fibrin properties 5,359
effect on platelet reactivity 3,75
treatment in thrombocythemia 1,427
Dextrose
effect on chromatography of factor VIII 1,197
Differential diagnosis
acute myocardial infarction 1,59
Dipyridamole
effect on fibrin deposition 5,343
effect on platelet aggregation & adenosine uptake, in vivo 4,361
Disseminated intravascular coagulation
induced by endotoxin, prevention by endotoxin inhibitor 1,243
fibrinopeptides in urine 4,131
in septicemia 3,405
platelet consumption, plasma platelet factor IV-like activity 4,247
Disulfide knots
relation of fragments E & D 1,371, 539
Duke bleeding time 4,1

Ecchymosis test 4,1
Editorials
from the Editors-in-Chief 2,1; 3,231;4,615;5,583
by Editor A.L. Copley 4,1
by Editor A.P. Fletcher 3,233
by Editor W.H. Seegers 5,703
EDTA
effect on platelet-collagen interaction 5,99
Elapidae venom
electrophoretic analysis 3,451
Electrophoretic analysis of venoms 3,451
Electrophorosed thrombin preparations 5,47
Embryo, human kidney cells 1,201
Endothelial cells
inhibition of platelet functions 5,747
isolation 3,665
uptake & utilization of free fatty acids 4,879

Endothelial damage
PUFA-rich, vitamin E deficient diet in pig 5,251
Endotoxin
effect on Ancrod-generated fibrin monomer complexes 1,541
effect on fibrinolysis 4,587
-induced disseminated intravascular coagulation 1,243
Limulus polyphemus coagulogen polymerization 2,55
Enzymatic method
study of radioiodinated fibrinogen 5,327
Enzyme
thrombin-like 1,267
thromboserpentin, on blood coagulation 2,487
Erythrocyte flexibility during & after surgery 5,657
Estrogen
formation of altered fibrinogen 5,519
Ethanol gelation test
indicator of fibrinemia 2,173
specificity & sensitivity 2,539
Euglobulin lysis
plasma calcium ions 5,613
Evolution of prothrombin 5,421
Experimental medicine 1,i
Experimental model
study of venous thrombosis in vivo 5,235

Factor IV
on inhibited thrombin substrate reactions 5,185
Factor V
activated(Va),stabilization & determination 5,315
activator:Russel's Viper venom 2,509
purification 5,703
Factor VII
activation
cold-promoted 4,769
plasmin,kallikrein, intrinsic blood coagulation 5,759
activity
effect of oral contraceptives 4,769
deficient plasma,effect of factor X 1,221
inactivation
antithrombin III 5,775
heparin 4,707;5,773
purification,characteristic 5,539
Factor VIII (antihemophilic factor)
activity:relation to blood groups 1,549
antisera
related antigen in platelets 5,585
assay:clinical application 1,19
characteristic
ionic strength requirements 4,155
chromatography
effect of dextrose 1,197
deficiency
hemophilia A,von Willebrand's disease 1,183
effect on platelet aggregation 2,97;3,363;4,375
inhibitors:assay 1,19
level after exercise or adrenaline infusion 1,493
properties of post-infusion factor VIII in von Willebrand's disease 5,111
purification 1,71
related antigen in platelets
in normal 4,617;5,585
in von Willebrand's disease 5,585
response to adrenaline,noradrenaline, isoprenaline,salbutamol 2,9
response to adrenaline,salbutamol 4,25
structure 3,389
Factor IX
-like activity,generation 5,469
deficient plasma,effect of factor X 1,221
preparation,characteristic 1,33
Factor X
activation,continuous assay 4,219
deficient plasma,effect of factor X 1,221
effect of collagen 1,581
purification & properties 1,221
Factor Xa(autoprothrombin C)
effect of collagen 1,581
inhibitory activity in liver disease, effect of heparin 4,335
requirements 1,293
Factor XI
separation 4,285
sensitivity to heparin cofactors A & B 4,463
Factor XII
determination 2,409
-induced fibrinolysis 4,285
Factor XIII(fibrin stabilizing factor FSF)
complex formation with heparin 3,589

Factor XIII
from platelets, fibrin crosslinking 1,147
from platelets and plasma, activity in health & disease 3,437
inactivation 3,241
stabilization of soluble fibrin (fibrinogen complexes) 4,509
Fatty acids
platelet phosphatidyl serine 1,353
FDP
clotting conditions 5,437
during pregnancy 5,453
Fibrin
clot
non cross-linked & cross-linked degradation 5,125
incorporation of protamine sulfate precipitable plasma protein 1,569
complex formation
aggregation of fragments D & E 5,719
crosslinked
enzymic degradation by plasmin, trypsin, chymotrypsin, Brinase 5,125
platelet factor XIII 1,147
of α-chain 2,467
degradation products
determination, test for differentiation between myocardial infarction & pulmonary embolism 1,59
fibrinolytic activity 5,647
fragments D & E in soluble fibrin complex formation 5,719
fragments D from non-crosslinked & crosslinked fibrin 2,283
isoelectric focusing in polyacrylamide gel 4,861
semiquantitation with latex agglutination technique 2,23
subunit relation to fibrinogen degradation products 2,201
deposition
effect of heparin & dipyridamole 5,343
effect of Trasylol 5,263
effects of histones and dextran 5,359
electrophorosed thrombin preparations 5,47,581
elimination
effect of inhibition of fibrinolytic system 2,365
effect of Trasylol 5,263
fibre formation 2,567
Fibrin
-fibrinogen degradation products during pregnancy 5,453
-fibrinogen transformation in umbilical cord blood 5,601
formation 3,675
altered structure 4,261
Ancrod or thrombin induced, dissolution 4,199
electrophorosed thrombin preparations 5,47
thrombin, Ancrod, Reptilase induced, susceptibility to plasmin 2,123
fragments D & E aggregation 5,719
^{125}I-labelled
behaviour in comparison to ^{125}I-labelled fibrinogen 5,495
monomer
aggregation in fibrinogen Paris I & in fetal fibrinogen 3,117
complexes
Ancrod-induced, effect of endotoxin 1,541
formation 3,183,465
coupled to agarose 2,137
adsorption of fibrinogen, fragments X,Y,D&E,D,E 3,117
enzymatic reduction by thioredoxin system, reoxidation 4,55
soluble, infused rabbit 5,343
non-crosslinked
degradation by plasmin, trypsin, chymotrypsin, Brinase 5,125
proteolysis by Ancrod 2,85
soluble complex formation
aggregation of fibrin degradation products 5,719
soluble
Ancrod induced, precipitation by Aprotinin & Norepinephrine 2,305
characteristic, fibrinogen incorporation 5,21
electrophoretic & N-terminal characteristic 4,183
estrogen induced glycine-I-C^{14} ethyl ester 5,519
incorporation of ^{125}-I labelled fibrinogen 4,499
stabilization by factor XIII 4,509
structure: effect of dextran 1,487
susceptibility to plasmin
effects of histones & dextran 5,359

Fibrinogen
abnormal
Giessen:proteolysis by plasmin 2,361
Iowa City:abnormal polymerization, no clinical symptoms 2,261
Paris I:fibrin monomers aggregation 3,117
assay
modified clot-weight method 5,213
catabolism
during induced intravascular coagulation 2,251
fibrinogenolytic pathway 2,185; 4,491,891,895,901
chemical degradation-CNBr cleavage
s-carboxymethyl derivative chains 1,161
disulfide rich fragments, relation to fibrinogen degradation products (fragments D & E) 1,371;2,271
N-terminal disulfide knot(N-DSK)
comparison with fragment D 1,371
comparison with fragment E 2,423
s-carboxymethyl chain fragments, molecular weights 1,113
molecular weight 1,113
susceptibility to thrombin 1,113
chromatography
on fibrin-agarose 3,657,745
quantification of fibrinogen & its derivatives by gel exclusion chromatography 3,525
degradation products(FDP)
assay
Fr-antigens in serum after coagulation at low pH 5,93
latex agglutination technique 2,23;3,643;4,567
tanned red cell hemagglutination inhibition immunoassay 3,339; 4,417
chromatography
on fibrin-agarose 3,657,745
on fibrinogen-agarose 3,657
on Sephadex 1,371,539
during Ancrod defibrination 2,115
effect on platelet function in defibrinated dogs
aggregation 1,95
hemostatic 1,135
fragment D
adsorption to thrombin modified fibrinogen-Sepharose 2,297
CNBr cleavage 1,371,539;2,271
heterogeneity 4,89
Fibrinogen
degradation products
fragment D
isolation,characteristic,relation to disulfide rich fragments of fibrinogen 1,371, 539;2,271
of low molecular weight,formation 3,553
purification 3,553
fragment E
CNBr cleavage 2,271,423
isolation,characteristic,relation to disulfide rich fragments of fibrinogen 1,371, 539;2,271
purification 1,371,539;3,553
structure,comparison with N-DSK,primary structure of overlapping fragment 2,423
fragments D:E complex
immunochemical,physicochemical characteristic 1,605
isoelectric focusing in polyacrylamide gel 4,861
level
during pregnancy,prognosis of fetus 5,453
in amniotic fluid 3,413
purification of fragments D, d and E 3,553
subunit relation to fibrin degradation products 2,201
& derivatives: Conference report 2,3
fetal
fibrin monomer aggregation 3,117
-fibrin conversion
enzymatically induced,light scattering 1,337
in fibrinogen Iowa City 2,261
in neonatal fibrinogen 5,601
-fibrin intermediates
influence on human blood viscosity and suspension stability 4,787
^{125}I-labelled
adsorption onto polymer surfaces 4,485
behaviour,comparison with ^{125}I-labelled fibrin 5,495
comparison of different radioiodination methods 5,327
elimination from lungs 2,365
interaction with platelet populations 1,283

Fibrinogen
^{125}I-labelled
level in experimental thrombi 5,1
turnover during induced intravascular coagulation 2,251
insolubilized
adsorption of fibrin monomer & fibrinogen degradation products 3,657
adsorption of fibrinogen derivatives 2,137
adsorption of fragment D 2,297
reduction of disulfide bonds 4,803
interaction with red cell membrane 4,261
level
during streptokinase therapy 2,105
in defibrinated dogs, effect on platelet aggregation 1,95
in relation to blood groups 1,549
modified
s-carboxymethylated 1,161; 2,85; 4,491
chains degradation
by Ancrod 2,85
by CNBr & plasmin 1,161
reduction of disulfide bonds
by thioredoxin system
identification of reduced disulfides, reoxidation 4,55
susceptibility to thrombin 5,685
urea, disulfide bonds reduced
ability to clump staphylococci 4,753
neonatal
comparison to adult fibrinogen 5,601
polymerization
in human plasma, detection 3,209
proteolysis
by Ancrod 2,85
by ristocetin preparation 5,565
by thrombin
reaction rate in mammalian species 5,223
reaction specificity 5,685
by trypsin
tryptic degradation products, effect on centrally acting drugs 2,219
purification
free from antithrombin-III & plasminogen 3,145
Fibrinogen
purification
free from plasminogen 1,619
radioiodinated
ICl & enzymatic methods 5,327
secretion, platelet
surface connecting system 3,347; 4,377
structure
in electron microscopy 2,567
light-scattering dissymetry, effect of thrombin & thrombin-like enzymes 1,337
viscous resistance 1,1
effect of γ-globulin & β-lipoprotein 4,193
Fibrinogenolysis
catabolism of fibrinogen 2,185; 4,491,891,895,901
in urokinase incubated plasma, clottable protein 5,301
Fibrinolysis
activity
before & after exercise 1,389
during Ancrod defibrination 2,115
euglobulin lysis time
influence of calcium ion 5,647
in hypoproteinemia 3,219
effect of carbohydrate feeding 1,407
effect on hemostatic plug formation 4,345
induced by
autoprothrombin II-A 1,443; 3,23
bis-6,7-dimethoxyisoquinoline derivatives 2,383
bis-tetrahydroisoquinoline derivatives, relation to histamine release 5,633
endotoxin 4,587
exercise 1,389,647
factor XII 4,285
fatty acids 3,489
insulin 4,137
inhibitors 2,31
thrombolytic agents
natural and synthetic 4,367
Fibrinopeptide A
in human plasma 5,197
Fletcher factor (prekallikrein)
deficiency, diagnostic test 5,375
Flexibility, erythrocyte
during & after surgery 5,657
Flurbiprofen
effect on platelet function & blood coagulation 5,667
Foetus prognosis, FDP 5,453

Foreword 1,iii
Fr-antigens in serum 5,93
Fragment
D & E aggregation 5,719
D & E isolation,characterization, & relation to disulfide knots 1,371
N-terminal of human plasminogen 1,89

Galactosamine induced hepatitis 1,475
Geloplastic activities
of electrophorosed bovine thrombin preparations 5,47,581
Gene duplication, partial
evolution of prothrombin 5,421
Gliclazide
effect on platelets 4,523
Globulin
Ac-, requirements 1,293
Ac-, comments:Editorial 5,703
γ , reducing action 4,193
Glucuronolactone
anticoagulant action 1,311,317
Glycine-1-C^{14} ethyl ester
soluble fibrin 5,519

Hemophilia
factor VIII assay 1,183
hormone therapy 1,253
Hemorrhage
arrest 4,1
control in von Willebrand's disease 1,253
Hemostasis
in vivo tests 4,1
Heparin
anticoagulant activity 1,173,349
cofactors A & B 4,463
comparison with Liquoid 2,155
complex formation with factor XIII 3,589
derivatives
synthesis,anticoagulant activity 1,173
effect on
cold activation of plasma 4,707
deposition of fibrin-like material 5,343
dyes, metachromasia 2,377
erythrocyte flexibility 5,657
factor V & activated factor V (Va) stability 5,315
factor VII (inactivation)4,707; 5,773

Heparin
effect on
factor Xa,inhibitory activity in liver disease 4,335
fibrin deposition 5,343
formation of white platelet thrombi 4,599
hemostasis in Reptilase defibrinogenated dogs 1,135
microthrombi 1,541
plasma,plasma proteins,platelet & factor XII activity at interfaces 1,507
inhibition of
factor Xa 4,335,463
thrombin 4,463
insoluble
interaction with plasma 4,237
purification of antithrombin III 5,439
neutralization by platelet factor IV 5,185
platelet aggregating activity 2,349
variation in commercial preparations 3,295
Heparinized plasma
celite activation 5,379
Heterozygotes
identification test 5,375
Histamine release 5,633
Histones
effect on fibrin properties 5,359
Hydrophidae venom
electrophoretic analysis 3,451
Hypercoagulable state
induced by hyperlipemia 1,353
Hyperlipemia induced
hypercoagulable state 1,353
Hyperlipoproteinemia,type II
levels of sphingolipids 5,173

ICl method
study of radioiodinated fibrinogen 5,327
Immunoreactivity,fibrinopeptide A
in human plasma 5,197
Infarction
acute myocardial 1,59
Inhibitors
effect on synthetic thrombin 1,243
Initiation of thrombosis 1,439
Insulin
effect on plasma fibrinolytic system 4,137

International Conference on Prostaglandins:Announcement 5,259
International Society of Blood Transfusion:Announcement 5,701
International Society on Thrombosis and Haemostasis:Announcement 5,97
Intraaortic balloon pumping
hematological & biochemical effects 4,387
therapeutic procedure 4,399
Intravascular coagulation
in galactosamine-induced hepatitis 1,473
in Neisseria Meningitidis 3,67
thrombin or thromboplastin induced,effect of Trasylol on fibrin deposition & elimination 5,263
thromboplastin induced,platelet (^{51}Cr),fibrinogen(^{125}I)turnovers 2,251
In vitro
study of radioiodinated fibrinogen 5,327
In vivo
studies of arterial thrombosis 5,529
venous thrombosis,experimental model 5,235
Ivy bleeding time 5,781

Kallikrein
activation of factor VII 5,759
Kidney cells of human embryo
characterization of isolated plasminogen activator 1,201

Jean Julliard Prize,Fifth:
Announcement 5,701

Laser-induced injury in ear arteries 5,529
Light scattering studies of systems with fibrinogen,thrombin or Bothrops atrox venom 1,337
Limulus polyphemus coagulogen
purification,polymerization 2,55
Lipid requirements 1,293
Lipoprotein,β 4,193

Membrane receptors 1,283
Methylxanthine derivative Pentoxifylline,inhibition of cancer cell stickiness 5,277
Microthrombi,mural coronary disease 5,243
Modified clot-weight method
plasma fibrinogen concentration 5,213
Monomer,soluble fibrin 5,343
Morphology,red cell aggregates 1,47
Mural microthrombi,coronary disease 5,243
Myocardial infarction
thrombolytic therapy 3,233

Neonatal fibrinogen,purified 5,601
Norethynodrel-mestranol 1,233
N-terminal fragments
of human fibrinogen 1,113
of human plasminogen 1,89

Obituary:J.B. Chatterjea 1,279,281
Oral contraceptive
effect on factor VII activity 4,769
effect on thrombin esterase activity 4,551

Pentoxifylline
inhibition of cancer cell stickiness 5,277
Petechiae 4,1
Pharmacology,clinical
bleeding time 5,699
Plasma
citrated,purification of factor VII 5,539
cold activated,factor VII 5,539
euglobulin lysis 5,613
exposed artificial surfaces 5,735
-fibrinogen concentration
modified clot-weight method 5,213
fibrinolytic neoantigens 5,777
fibrinopeptide A immuno-reactivity 5,197
heparinized
contact activation 5,379
kallikrein,factor VII activation 5,759
proteins
elutable from surfaces 5,735
^{125}I-labelled,competitive adsorption onto polymer surfaces 4,485
during fibrinogenolysis 5,301
& thromboid surface layers 1,1
purified
factor VII activation 5,759
transfusion & autotransfusion in von Willebrand's disease 5,479
uraemic
abnormal breakdown of adenosine diphosphate 1,323

Plasma
viscous resistance 1,1
Plasmic degradation
& products of human fibrinogen 1,371,539
Plasmin
activation of factor VII 5,759
assay
with synthetic substrate(N-CBZ-L-lysine p-nitrophenyl ester) 3,729
complex inhibitor antibodies, neoantigens 5,777
degradation of non cross-linked & cross-linked fibrin clots 5,125
susceptibility of fibrin 5,359
Plasminogen
activator
from human embryo kidney cells characteristic,comparison with urokinase 1,201
from pig heart,properties 4,731
level in plasma,effect of c-AMP,dibutyryl c-AMP & glucagon 4,539
release by histamine 5,633
release,following intravenous adrenaline 3,51
response to adrenaline,salbutamol 2,9;3,137;4,25
streptokinase
as thrombolytic agent 4,367
degradation 5,413
effect on plasma fibrinogen 2,105
^{131}I-labelled,interaction with ^{125}I-labelled plasminogen 5,413
therapy,plasminogen metabolism 2,239
thrombolytic agent 4,367
urokinase
as thrombolytic agent 4,367
comparison to activator from human embryo kidney cells 1,201
inhibitor 2,31
insoluble,characteristic 2,479
CNBr cleavage 1,89
^{125}I-labelled
behaviour in thrombosis 4,303
interaction with ^{131}I-labelled streptokinase 5,413
metabolism,during streptokinase therapy 2,239
N-terminal fragment structure (amino acid sequence) 1,89
Plasminogen
proactivator
factor XII dependent,separation 4,285
release by histamine 5,633
system,activation by dextran sulfate in Hageman factor deficient plasma 4,609
purification
ion exchange,affinity chromatography 4,675
Platelet
activity
time dependence of tests measuring 3,307
in vitro and in vivo,effect of Arvin 3,565
in vivo,mesenteric model
suppresion after dextran administration 3,75
actomyosin
purification,characteristic, ATPase activity 5,33
adenosine uptake
inhibition by dipyridamole & related drugs 3,35
adenylate cyclase
stimulation by prostaglandin D_2 5,401
adhesion
-collagen adhesiveness assay
effect of chlorpromazine,EDTA, aspirin 5,99
effect of flurbiprofen 5,667
inhibition by bencyclane 4,741
polyphloretinphosphate 4,687
aggregating agents
induction of clot retraction 2,323
aggregation
abnormal
inhibition by methylxanthine derivative pentoxifylline 5,277
in coronary disease 5,243
activity
before & after exercise 1,389
effect of aspirin 5,69
of heparin 2,349
ADP-induced 1,95
ceruloplasmin substitution for fibrinogen 4,327
effect of dypiridamole & related drugs 3,35;4,361
inhibitors
aspirin,after exercise 5,69

Platelet
aggregation
inhibitors
flurbiprofen 3,577
medium-chain fatty acids 4,479
prostaglandin D_2 5,291
kinetics evaluation 4,319
in normal & uraemic plasma 1,323
in vivo, effect of aniline & pyrimidine derivatives 3,103
adrenaline induced
effect of aspirin 5,69
cold-induced
inhibition by nonionic surface active substance 2,331
collagen-induced
effect of dypiridamole & related agents 3,35;4,361
effect of dispersion & multimerization of collagen (tropocollagen multimers) 3,715
inhibitors
aspirin 1,233;5,69
flurbiprofen 3,577;5,667
medium-chain fatty acids 4,479
phenylbutazone 1,233
prostaglandin D_2 5,291
prostaglandin E_1 3,577
endothelial cells 5,747
epinephrine-induced
effect of dipyridamole 3,35
factor VII induced 2,97
heparin induced 2,155,349
in vivo, effect of dipyridamole & related agents 4,361
Liquoid induced 2,155
polylysine induced
effects of conformation of polylysine 5,709
ristocetin-induced
effect of factor VIII & aspirin 3,501
in normal, haemophilic & von Willebrand's plasma, effect of factor VIII antibodies 3,363;4,375
thrombin-induced 1,95
effect of heparin & Liquoid 2,155
effect of staphylocoagulase 4,819
inhibitors
flurbiprofen 5,667
from endothelial cells 5,747
medium-chain fatty acids 4,479

Platelet
antiplatelet antibody
induction of platelet defect (aggregation, release reaction) 3,375
-clumping substance
effect on platelet aggregation 4,625
isolation, characteristic 4,639
collagen, adhesiveness 5,99
^{51}Cr-labelled
content in experimental thrombi 5,1
density distribution of circulating platelet population 3,1
survival in stationary state 3,605
turnover during intravascular coagulation 2,251;4,247
effect on clot structuration 3,425
exercise-induced
effect of aspirin 5,69
factor III
activity 1,33,353
factor IV
influence on inhibited thrombin 5,185
-like activity in plasma during intravascular coagulation 4,247
thrombin substrate reactions 5,185
factor VIII related antigen 4,617; 5,585
factor XIII
activity in health & disease 3,437
effect on fibrin crosslinking 1,147
fibrinogen secretion 3,347;4,377
fibrinolysis inhibitors 2,31
flurbiprofen 5,667
interaction with modified collagen 2,41
level
during skin graft rejection 4,177
membrane
effect of chemicals &drugs 1,631
requirement 1,293
migration in vitro, chemotactic response 3,477
non-specific transamidase activity 1,147
phosphatidyl serine activity in response to fatty acids 1,353

Platelet
populations
separation 1,283
incorporation of ^{125}I-labelled fibrinogen 1,283
prostaglandin synthesis 3,327
reactivity
polylysine 5,709
release reaction
abnormal,in thrombocytopathy 4,119
effect of polylysine 5,709
inhibition by aspirin,prevention by fatty acid precursor 3,327
inhibition by flurbiprofen 5,667
initiation by thrombin,inhibition by iodoacetic acid & antimycin 3,347
-rich clots
contraction-relaxation waves 5,83,261
synthetic activity
inhibition by gliclazide 4,523
Polybrene
effect on plasma,plasma proteins, & factor XII activity at interfaces 1,507
Polylysine
effect on platelet 5,709
Polymer surfaces
competitive adsorption of plasma proteins 4,485
Polyphoretinphosphate
inhibition of platelet adhesion 4,687
Post-infusion factor VIII in von Willebrand's disease 5,111
Pregnancy & FDP 5,453
Prekallikrein
activation 3,281
deficiency
Fletcher factor 5,375
prealbumin activator:isolation, characterization 4,103
purification,properties 3,281
separation 4,285
Prethrombin
N-terminal amino acid sequence, thrombin formation 3,357
prethrombin-E formation, inhibition with antithrombin & synthetic inhibitors(DFP,TLCK) 4,869
Prostaglandin D_2
inhibition of platelet aggregation 5,291
Prostaglandin D_2
inhibition of platelet aggregation, adenylate cyclase stimulation 5,401
Prostaglandin E_1
effect on relaxation of retracted clots 5,431
effect on reptilase clot retraction 4,189
Protamine sulfate
effect on plasma,plasma proteins, platelet & factor XII activity at interfaces 1,507
fetal & abnormal(Paris I)fibrin monomer aggregation 3,117
precipitable plasma protein incorporation into fibrin clot 1,569
precipitation & paracoagulation tests 2,539
Protein
defective, prothrombin Brussels 5,141
Proteinated polymer surfaces 3,87
Prothrombin
abnormal
Brussels,properties 5,141
effect of thromboplastin 2,557
activation 1,293
by intrinsic prothrombin activator 5,511
by thromboplastin or Taipan venom,characteristic 4,653
by Taipan snake venom 3,705
amino acid sequence
N-terminal 3,461
O-fragment 4,885
O- & PR-fragments homology 5,421
assay 1,559
with synthetic,chromogenic substrate 4,719
Prothrombin
cleavage of arginyl bonds 5,511
comparison with factor X 2,293
complex
purification 1,461
surface charge effect of phospholipids 2,525
derivatives 4,829
evolution
amino acid sequence homology of O & PR fragments 5,421
generation of factor IX-like activity 5,469
human & bovine,comparison 4,875
purification,properties 1,461
purified
factor IX 5,469

Pseudohemorrhage 4,1
PUFA-rich diet
endothelial damage in pigs 5,251
Purification
antihemophilic factor 1,71
antithrombin III 5,439
factor VII 5,539
Purified
factor VII,activation 5,759
factor VII inactivation by heparin & antithrombin III 5,773
neonatal fibrinogen 5,601
prothrombin & factor IX activity 5,469

Quantitative platelet-collagen adhesiveness 5,99

Radioiodinated fibrinogen
ICl & enzymatic methods 5,327
Receptors,membrane 1,283
Red blood cell(erythrocyte)
aggregates,morphology 1,47
^{59}Fe-labelled content in experimental thrombi 5,1
flexibility,effect of heparin 5,657
membrane,interaction with fibrinogen 4,261
Reptilase-defibrinogenated dogs
acetyl salicylic acid,heparin & fibrinogen interference 1,135
platelet aggregation induced by ADP & thrombin 1,95
Ristocetin
-induced platelet aggregation relationship to factor VIII 3,363;4,375
proteolytic activity in ristocetin preparation,fibrinogen degradation 5,565

Salbutamol
fibrinolytic & factor VIII resp[illegible]es 2,9;3,137;4,25
Secondary bleeding time 4,1
Serotonin release
endothelial cells 5,747
Serum
fibrinogen-fibrin degradation products,quantitation 2,23; 3,643
Fr-antigens 5,93
glass-activated,factor VII 5,539
proteins,interaction with ^{125}I-labelled Defibrase 1,637
viscous resistance 1,1

Snake venoms
Oxyuranus scutellatus scutellatus prothrombin activation 4,653
Taipan,activation of prothrombin 1,599;3,705
Viperidae,Crotalidae, Elapidae Hydrophidae:electrophoretic analysis,action on blood coagulation 3,451
Sodium salicylate on pregnant mice 1,127
Soluble fibrin monomer
effect of heparin & dipyridamole 5,343
Sphingolipids
level normal & in type II(a+b) hyperlipoproteinemia 5,173
Spleen transamidase, bovine 5,571
Stabilization of activated factor V 5,315
Staphylocoagulase
effect on platelet aggregation & clot retraction 4,819
Staphylococci clumping
by plasmas of various animal species 3,419
dependence on fibrinogen conformation 4,753
Streptokinase degradation
plasminogen activator production 5,413
Substrate reactions,thrombin & platelet
platelet factor IV 5,185
Surface connecting system
platelet fibrinogen secretion 3,347; 4,377
Synthetic substrate
benzoyl-DL-arginine-β-naphtylamide thrombin assay 5,157
benzoyl-L-phenylalanine-valine-arginine-p-nitroaniline.HCl
antithrombin assay 5,621
prothrombin assay 4,719
Reptilase assay 1,267
thrombin assay 1,267
thrombin inhibited,platelet factor IV interaction assay 5,185
trypsin assay 1,267
Synthetic thrombin inhibitors
antithrombotic effect 1,243

Teratogenic interaction of
Defibrase & sodium salicylate in pregnant mice 1,127
Thioredoxing system
reduction of disulfide bonds in fibrin-ogen 4,55;5,685

Thrombelastographic study of retracted clots 5,431
Thrombin
assay with synthetic substrates 1,267;5,157
clotting units & Ancrod 5,695
complex inhibitor antibodies, neoantigens 5,77
electrophorosed 5,47
esterase activity
effect of oral contraceptive 4,551
fibrin formation & dissolution 4,199
fibrin monomer complex formation 3,183
fibrinogen-fibrin conversion
light scattering 1,337
-fibrinogen reaction
rate in mammalian species 5,223
specificity 5,685
fibrinolytic antigens 5,777
formation 1,293;3,357
inhibition by antithrombin & enzyme inhibitors(DFP,TLCK) 4,869
lipids requirements 4,437
geloplastic activity(fibrin forming activity) 5,47
inhibitors
4-amidinophenylpyruvic acid, characteristic 1,243
antithrombin III 4,869
effect of platelet factor IV 5,185
cofactors A & B of heparin 4,463
heparin,effect of platelet factor IV 5,185
mimetic effect of estrogen 5,519
intravascular coagulation induced by thrombin 5,263
isolation & characterization 4,653;5,787
modification
maleination,nitration 3,91
molecular weights 1,113
multiple forms
isolation,characteristic 4,653
proteolytic specificity 4,713
purification,crystallization 1,533
substrate reactions
platelet factor IV 5,185
synthetic chromogenic substrate as substitute 5,621
Thrombin-E
formation,inhibition by antithrombin & enzyme inhibitors (DFP,TLCK) 4,869
isolation & characteristic 4,829
Thrombin-like enzymes
Ancrod, Arvin
clotting units,comparison with thrombin 5,695
effect on fibrinolytic activity & fibrinogen 2,115
effect on platelet functions 3,565
-fibrin formation & dissolution 4,199
-fibrin,digestion by plasmin 2,423
immunochemical identification 2,17
induced fibrin monomer complexes 1,54
proteolysis of fibrinogen,fibrin, s-carboxymethyl polypeptide chains of fibrinogen 2,85
Defibrase,Reptilase
assay with synthetic substrate 1,267
clot retraction 2,71
effect of ADP & prostaglandin E_1 4,189
defibrination
effect of chlorpromazine on hemostasis in dog 4,229
fibrin distribution 3,197
hemostatic function of platelets 1,135
platelet aggregation 1,95
surgery 3,161
-fibrin,digestion by plasmin 2,123
^{125}I-labelled 1,637;4,35
immunochemical identification 2,17
interaction with serum proteins 1,637
interactions with sodium salicylate in teratogenesis 1,127
metabolism 4,35
therapy
complications in amyloid nephropathy 2,177
plasminogen metabolism 2,239
thromboserpentin
activity in coagulation of venoms from different species of snakes 2,487
induced fibrinogen-fibrin conversion 1,337
Thrombocytopathy
platelet abnormalities 4,119

Thromboembolism, pulmonary
collagen-induced 1,233
Thromboid surface layers 1,1
Thrombolytic agents
directions of investigative efforts 4,367
Thromboplastin
induced intravascular coagulation 5,263
prothrombin activation 4,653
Thrombosis
arterial
in rat
continuous registration method 4,599
in vivo studies 5,529
dextran treatment 1,427
effect of cholesterol 2,451
effect of oral contraceptives 3,545,631
experimental, electrode-stasis model 5,235
in agranulocytic rabbits 4,165
initiation 1, 437,439
in vitamin E deficiency 5, 251
in vivo, venous experimental model 5,235
laser induced, in mice 5,529
vascular injury, scanning electron microscopic studies 4,699
Thromboserpentin enzyme
study on blood coagulation 2,487
Thrombus formation
arterial & venous
platelet, red cell & fibrin content 5,1
effect of fibrinolysis & coagulation 4,345
effect of heparin 4,599
induction 4,271
influence of blood flow velocity 4,447
in normal & thrombocytopenic rabbits 4,77
^{125}I, ^{131}I-labelled blood proteins uptake 4,303
wound thrombus & wound thrombi resistance 4,1
Thrombus-like surface layers 1,1
Thrombus size classification 4,757
Transamidase, bovine spleen 5,571
Transfusion of plasma
von Willebrand's disease 5,479
Trasylol
fibrin deposition & elimination in lungs 5,263
Trypsin
degradation of fibrin clots 5,125
determination by synthetic chromogenic substrates 1,267

Ultrastructure
bovine autoprothrombin II-A 5,461
Umbilical cord blood
fibrinogen to fibrin transformation 5,601
Urokinase
comparison with plasminogen activator isolated from human embryo kidney cells 1,201
Uronic acid carboxyl groups 1,173

Venom
& blood coagulation 2,487
Bothrops atrox
light scattering studies 1,337
electrophoretic analysis of Viperidae, Crotalidae, Elapidae & Hydrophidae, action on blood 3,451
Venous thrombosis in vivo
experimental model 5,235
Viperidae venom
electrophoretic analysis 3,451
Viscous resistance 1,1
Vitamin E
deficiency, endothelial damage 5,251
Von Willebrand's disease
factor VIII assay 1,183
factor VIII related antigen in platelets 5,585
high & lower molecular weight procoagulant factor VIII after treatment 3,389
hormone therapy 1,253
lack of factor VIII-related antigen in platelets 4,617
post-infusion factor VIII properties 5,111
ristocetin-induced platelet aggregation 3,363,501
transfusion & autotransfusion of plasma 5,479
variant patterns 5,557

Wound thrombus 4,1
resistance 4,1

Editors-in-Chief

PROFESSOR ALFRED L. COPLEY
50 Central Park West
New York, New York 10023
Laboratory of Biorheology
Polytechnic Institute of New York
333 Jay Street
Brooklyn, N.Y. 11201

PROFESSOR BIRGER BLOMBÄCK
Institutionen for Koagulationsforskning
(Department of Blood Coagulation Research)
Karolinska Institutet
Solnavagen 1
S-104 01 Stockholm 60, Sweden

Editors

AUSTRALIA:

PROFESSOR BARRY G. FIRKIN
Department of Medicine, Monash Medical School
Alfred Hospital
Monash University
Prahran, Victoria 3181

AUSTRIA:

PROFESSOR DR. E. DEUTSCH
I. Medizinische Universitätsklinik
Spitalgasse 23
A-1097 Wien IX

BELGIUM:

PROFESSOR DR. J. HUGHES
Hôpital de Bavière
Institut de Médecine
Université de Liège
4000 Liège

PROFESSOR DR. M. VERSTRAETE
Laboratory of Blood Coagulation
Department of Internal Medicine
Academisch Ziekenhuis
University of Leuven
Kapucijnenvoer 35
3000 Leuven

CANADA:

PROFESSOR MARIAN A. PACKHAM
Department of Biochemistry
University of Toronto
Toronto, Canada M5S 1 A8

DENMARK:

PROFESSOR DR. STAFFAN MAGNUSSON
Department of Molecular Biology,
University of Aarhus
DK-8000 Aarhus

FRANCE:

PROFESSEUR F. JOSSO
Département d'Hématologie
Faculté de Médecine
Necker-Enfants Malades
156, rue de Vaugirard
Paris 15e

PROFESSEUR MARIE-JOSÉ LARRIEU
Institut de Pathologie Cellulaire
Hôpital Bicetre
94-Le Kremlin Bicêtre

PROFESSEUR AG. DORIS MÉNACHÉ
Laboratoire Central D'Hématologie
Hôpital Beaujon
100, Boulevard du Général Leclerc
92 – CLICHY

GERMAN DEMOCRATIC REPUBLIC:

PROFESSOR DR. F. MARKWARDT
Institut für Pharmakologie und Toxikologie
Medizinische Akademie Erfurt
Nordhäuser Strasse 74
50 Erfurt

GERMAN FEDERAL REPUBLIC:

PROFESSOR DR. HANS EGLI
Institut für Exp. Hämatologie
und Bluttransfusionswesen
Universität Bonn
Annaberger Weg
53 Bonn-Venusberg

PROFESSOR DR. NICO GOOSSENS
Friedrichstr. 6
8 München 40

PROFESSOR DR. H. H. HARTERT
Medizinische Klinik
Städtisches Krankenhaus
Friedrich-Engels-Strasse 25
6750 Kaiserslautern

PROFESSOR DR. G. HAUCK
Physiologischés Institut
Universität Münster
Robert-Koch-Strasse 28
44 Münster

PROFESSOR DR. L. ROKA
Institut für klinische Chemie an den
Universitätskliniken Giessen
Klinikstrasse 32 b
63 Giessen

PROFESSOR DR. SIEGFRIED WITTE
Medizinische Abteilung
Diakonissenkrankenhaus
Diakonissenstrasse 28
75 Karlsruhe 51

ISRAEL:

PROFESSOR A. RIMON
Department of Microbiology
Tel-Aviv University
155 Herzl Street
Tel Aviv

PROFESSOR A. SILBERBERG
Polymer Department
The Weizmann Institute of Science
Rehovot

ITALY:

PROFESSOR P. M. MANNUCCI
Centro per lo studio e la terapia delle
malattie emorragiche e della trombosi
Universita degli Studi di Milano
Via Pace, 15, 20122 Milano

JAPAN:

PROFESSOR E. FUKADA
Rikagaku Kenkyusho
(The Institute of Physical and
Chemical Research)
Wako-Shi, Saitama, 351

PROFESSOR S. OKAMOTO
Department of Physiology
Kobe University School of Medicine
12 Kusunoki-cho, 7-Chome Ikuta-ku, Kobe 650

NORWAY:

DR. H. C. GODAL
Haematological Research Laboratory
Department IX, Ulleval Hospital
Oslo

POLAND:

PROFESSOR DR. MARIA KOPEC
Instytut Badan Jadrowych
Osrodek Zeran
Ulica Dorodna 16
Warszawa 9

SWEDEN:

PROFESSOR INGA MARIE NILSSON
Koagulationslaboratoriet
Allmänna Sjukhuset
214 01 Malmo

DR. PER OLSSON
Thoracic Surgery Research Laboratory
Karolinska Sjukhuset
Stockholm 60

THAILAND:

PROFESSOR PHUMARA TALALAK
Department of Pathology
Faculty of Medicine
Siriraj Hospital
Mahidol University
Bangkok 7

UNITED KINGDOM:

DR. P. J. GAFFNEY
Division of Biological Standards
National Institutes for Medical Research
Hampstead Laboratories
Holly Hill
London NW3 6RB

PROFESSOR DR. G. P. McNICOL
Department of Medicine
The University of Leeds
The Martin Wing
The General Infirmary
Leeds LS1 3EX

DR. A. S. TODD
Department of Pathology
Royal Infirmary
Dundee, DD1 9ND
Scotland

UNITED STATES:

PROFESSOR MARION I. BARNHART
Department of Physiology
School of Medicine
Wayne State University
540 E. Canfield
Detroit, Michigan 48207

PROFESSOR K. M. BRINKHOUS
Department of Pathology
School of Medicine
The University of North Carolina
at Chapel Hill
Chapel Hill, N. C. 27514

PROFESSOR R. F. DOOLITTLE
Department of Chemistry
Revelle College
University of California, San Diego
Post Office Box 109
La Jolla, California 92037

PROFESSOR R. C. ELSTON
Department of Biostatistics
School of Public Health
The University of North Carolina
Chapel Hill, North Carolina 27514

PROFESSOR ANTHONY P. FLETCHER
Washington University
School of Medicine
Box 8073
660 So. Euclid
St. Louis, Missouri 63110

PROFESSOR A. J. JOHNSON
Department of Medicine
School of Medicine
New York University
550 First Avenue
New York, New York 10016

PROFESSOR LASZLO LORAND
Department of Biochemistry &
Molecular Biology
Northwestern University
Evanston, Illinois 60201

DR. ELEMER MIHALYI
National Institutes of Health
Bethesda, Maryland 20014

PROFESSOR STEFAN NIEWIAROWSKI
Specialized Center for Thrombosis Research
Temple University Health Sciences Center
3400 North Broad Street
Philadelphia, Pennsylvania 19140

PROFESSOR HYMIE L. NOSSEL
Department of Medicine
College of Physicians & Surgeons
Columbia University
Broadway at 168th Street
New York, New York 10032

PROFESSOR H. A. SCHERAGA
Department of Chemistry
Cornell University
Ithaca, New York 14850

PROFESSOR WALTER H. SEEGERS
Department of Physiology
School of Medicine
Wayne State University
540 E. Canfield
Detroit, Michigan 48201

DR. L. VROMAN
Veterans Administration Hospital
800 Poly Place
Brooklyn, New York 11209

PROFESSOR LEONARD WEISS
Experimental Pathology
Roswell Park Memorial Institute
Department of Health
666 Elm Street
Buffalo, New York 14203

USSR:

PROFESSOR V. A. BELITSER
Institute of Biochemistry
Leontovicha 9
Kiev

PROFESSOR B. A. KUDRJASHOV
Department of Physiology
Moscow University
Moscow 117234

YUGOSLAVIA:

DR. RADMILA BAKLAJA
Institute of Blood Transfusion
Sr. Save 39
Beograd